The ultimate Open Source solution for managing radiology workflows, patient data, and PACS integration. 100% Web-based.
A Radiology Information System (RIS) is a networked software system for managing medical imagery and associated data. ThaiRIS is especially useful for tracking radiology imaging orders and billing information, and is often used in conjunction with Picture Archiving and Communication Systems (PACS) and VNAs to manage record-keeping, billing, and workflow.
Optimized processes for Hospital and Tele-Radiology environments
Typical workflow within a single hospital or clinic.
Workflow for remote reading and multi-site management.
This aggressive spending has caused some short-term pain. The stock has pulled back by about 5-9% in early 2026 , underperforming the broader market as investors worry about near-term profit margins and the "AI spending scare". Why the "Buy" Rating Still Dominates
AI responses may include mistakes. For financial advice, consult a professional. Learn more
Amazon’s advertising business has become a juggernaut, generating over $70 billion in annual revenue with significantly higher profit margins than its retail side. amazon stock buy rating
The narrative among top firms like BofA , Citi, and Oppenheimer is that Amazon is essentially the "Berkshire Hathaway of our time"—a diversified powerhouse that uses its retail and cloud profits to fund futuristic bets that eventually pay off.
Heading into its on April 29, Amazon (AMZN) finds itself at a critical crossroads. This aggressive spending has caused some short-term pain
Despite the price dip, still maintain a Buy or Strong Buy rating . Their "story" for the stock is built on three pillars:
Amazon Web Services (AWS) is seeing growth speed back up to the mid-20% range , fueled by intense demand for generative AI workloads. For financial advice, consult a professional
Innovations in robotics and logistics are helping the core retail business stay resilient even as shipping and labor costs fluctuate. The Wall Street Consensus (as of late April 2026) Current Estimate Mean Price Target $282.37 – $295.80 Implied Upside ~11% to 30% from current levels High Target $360.00 Low Target $175.00





We are working on the next major version with enhanced AI integration and cloud capabilities.
Free Version 1.8 OpenSource Uploaded to Github. Download Here
Added Lab Result support to the workflow.